|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
26
|
|
pubmed:dateCreated |
2009-9-9
|
|
pubmed:abstractText |
The long-term risk of prostate cancer-specific mortality (PCSM) after radical prostatectomy is poorly defined for patients treated in the era of widespread prostate-specific antigen (PSA) screening. Models that predict the risk of PCSM are needed for patient counseling and clinical trial design.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4300-5
|
|
pubmed:dateRevised |
2010-10-27
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
|
|
pubmed:affiliation |
Glickman Urological and Kidney Institute and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
